The Memphis Business Group on Health (MBGH) is pleased to make this forum, including all web pages and web sites accessed from this page, available to Web Site users and others. However, the MBGH does not render legal or consultation services, and legal counsel must be consulted to determine any material’s applicability to any specific situation. MBGH cannot warrant or control the quality, accuracy, or validity of the information posted here. Comments posted on this blog are the sole responsibility of their writers. Use of such information is at the risk of the accessing user and the accessing user assumes all liabilities that may result from such use.




New, Very Expensive Treatments for Cholesterol Approved

NOTE: MBGH's new, specialty pharmacy management program for members is exactly what employers need to make the tough decisions around how to manage the costs of the new, very expensive treatments for high cholesterol, while still getting this treatment to those that need it. Contact Cristie at [email protected] to learn more.

Two drugs in a new class of cholesterol-lowering treatments have now been approved by the FDA --  Praluent, made by Sanofi Regeneron and approved last month, which costs $14,600 a year, and Repatha, made by Amgen and approved last Thursday, at $14,100 a year. Typically, patients that can't tolerate statins, the most prescribed drug class for the treatment of high cholesterol at a cost of only pennies per day, are candidates for the new drugs. Like statins, the new drugs are taken for the rest of a patient's life, resulting in well over 6 figure cost of treatment.

Read this article in the New York Times to get an understanding for the dilemma patients, physicians, insurance companies, and self-insured employers are facing regarding use of these new drugs.

Posted by Cristie Travis at 9:29 AM

From Our Blog

Say Hello

Please feel free to drop us a line via the button below. We try to respond to every email we receive.

Stay Connected

Join the MBGH community and keep up to date with issues concerning Memphis healthcare.

Facebook Twitter LinkedIn Feed